Acute Crit Care.  2022 Nov;37(4):533-542. 10.4266/acc.2022.00787.

The prognostic impact of rheumatoid arthritis in sepsis: a population-based analysis

• Oud L
• Garza J

• KMID: 2540141
• DOI: http://doi.org/10.4266/acc.2022.00787

Abstract

Background
Rheumatoid arthritis (RA) is associated with increased risk of sepsis and higher infection-related mortality compared to the general population. However, the evidence on the prognostic impact of RA in sepsis has been inconclusive. We aimed to estimate the population-level association of RA with short-term mortality in sepsis. Methods: We used statewide data to identify hospitalizations aged ≥18 years in Texas with sepsis, with and without RA during 2014–2017. Hierarchical logistic models with propensity adjustment (primary model), propensity score matching, and multivariable logistic regression without propensity adjustment were used to estimate the association of RA with short-term mortality among sepsis hospitalizations. Results: Among 283,025 sepsis hospitalizations, 7,689 (2.7%) had RA. Compared to sepsis hospitalizations without RA, those with RA were older (aged ≥65 years, 63.9% vs. 56.4%) and had higher burden of comorbidities (mean Deyo comorbidity index, 3.2 vs. 2.7). Short-term mortality of sepsis hospitalizations with and without RA was 26.8% vs. 31.4%. Following adjustment for confounders, short-term mortality was lower among RA patients (adjusted odds ratio [aOR], 0.910; 95% confidence interval [CI], 0.856–0.967), with similar findings on alternative models. On sensitivity analyses, short-term mortality was lower in RA patients among sepsis hospitalizations aged ≥65 years and those with septic shock, but not among those admitted to intensive care unit (ICU; aOR, 0.990; 95% CI, 0.909–1.079). Conclusions: RA was associated, unexpectedly, with lower short-term mortality in septic patients. However, this “protective” association was driven by those patients without ICU admission. Further studies are warranted to confirm these findings and to examine the underlying mechanisms.

Keyword

intensive care unit; mortality; rheumatoid arthritis; sepsis; septic shock

Reference

1. Helmick CG, Felson DT, Lawrence RC, Gabriel S, Hirsch R, Kwoh CK, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: part I. Arthritis Rheum. 2008; 58:15–25.

2. Hunter TM, Boytsov NN, Zhang X, Schroeder K, Michaud K, Araujo AB. Prevalence of rheumatoid arthritis in the United States adult population in healthcare claims databases, 2004-2014. Rheumatol Int. 2017; 37:1551–7.

3. Mok CC, Kwok CL, Ho LY, Chan PT, Yip SF. Life expectancy, standardized mortality ratios, and causes of death in six rheumatic diseases in Hong Kong, China. Arthritis Rheum. 2011; 63:1182–9.

4. Jani M, Barton A, Hyrich K. Prediction of infection risk in rheumatoid arthritis patients treated with biologics: are we any closer to risk stratification? Curr Opin Rheumatol. 2019; 31:285–92.

5. Jinno S, Lu N, Jafarzadeh SR, Dubreuil M. Trends in hospitalizations for serious infections in patients with rheumatoid arthritis in the US between 1993 and 2013. Arthritis Care Res (Hoboken). 2018; 70:652–8.

6. Subesinghe S, Rutherford AI, Byng-Maddick R, Leanne Hyrich K, Benjamin Galloway J. Recurrent serious infections in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford). 2018; 57:651–5.

7. Filbin MR, Lynch J, Gillingham TD, Thorsen JE, Pasakarnis CL, Nepal S, et al. Presenting symptoms independently predict mortality in septic shock: importance of a previously unmeasured confounder. Crit Care Med. 2018; 46:1592–9.

8. Kumar A, Ellis P, Arabi Y, Roberts D, Light B, Parrillo JE, et al. Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. Chest. 2009; 136:1237–48.

9. Rudd KE, Johnson SC, Agesa KM, Shackelford KA, Tsoi D, Kievlan DR, et al. Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study. Lancet. 2020; 395:200–11.

10. Sihvonen S, Korpela M, Laippala P, Mustonen J, Pasternack A. Death rates and causes of death in patients with rheumatoid arthritis: a population-based study. Scand J Rheumatol. 2004; 33:221–7.

11. Franklin J, Lunt M, Bunn D, Symmons D, Silman A. Risk and predictors of infection leading to hospitalisation in a large primary-care-derived cohort of patients with inflammatory polyarthritis. Ann Rheum Dis. 2007; 66:308–12.

12. Colbert JF, Schmidt EP, Faubel S, Ginde AA. Severe sepsis outcomes among hospitalizations with inflammatory bowel disease. Shock. 2017; 47:128–31.

13. Barrett O, Abramovich E, Dreiher J, Novack V, Abu-Shakra M. Short- and long-term mortality due to sepsis in patients with rheumatoid arthritis. Rheumatol Int. 2017; 37:1021–6.

14. Krasselt M, Baerwald C, Petros S, Seifert O. Mortality of sepsis in patients with rheumatoid arthritis: a single-center retrospective analysis and comparison with a control group. J Intensive Care Med. 2021; 36:766–74.

15. Sheth M, Benedum CM, Celi LA, Mark RG, Markuzon N. The association between autoimmune disease and 30-day mortality among sepsis ICU patients: a cohort study. Crit Care. 2019; 23:93.

16. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med. 2007; 4:e296.

17. Texas Department of State Health Services, Center for Health Statistics. Texas inpatient public use data file (PUDF) [Internet]. Austin (TX): Texas Department of State Health Services, Center for Health Statistics;2018. [cited 2002 Aug 13]. Available from: http://www.dshs.state.tx.us/thcic/hospitals/Inpatientpudf.shtm.

18. Robert Graham Center. Social deprivation index [Internet]. Washington (DC): Robert Graham Center;2021. [cited 2002 Aug 13]. Available from https://www.graham-center.org/maps-data-tools/social-deprivation-index.html.

19. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016; 315:801–10.

20. Rhee C, Dantes R, Epstein L, Murphy DJ, Seymour CW, Iwashyna TJ, et al. Incidence and trends of sepsis in US hospitals using clinical vs claims data, 2009-2014. JAMA. 2017; 318:1241–9.

21. Prescott HC, Cope TM, Gesten FC, Ledneva TA, Friedrich ME, Iwashyna TJ, et al. Reporting of sepsis cases for performance measurement versus for reimbursement in New York state. Crit Care Med. 2018; 46:666–73.

22. Buchman TG, Simpson SQ, Sciarretta KL, Finne KP, Sowers N, Collier M, et al. Sepsis among Medicare beneficiaries: 1. The burdens of sepsis, 2012-2018. Crit Care Med. 2020; 48:276–88.

23. Kannayiram SS, Guraya A, Muojieje CC, Nair KM, Idolor ON, Odion J, et al. An analysis of rheumatoid arthritis hospitalizations. Cureus. 2020; 12:e12344.

24. Edigin E, Ojemolon PE, Eseaton PO, Shaka H, Akuna E, Asemota IR, et al. Rheumatoid arthritis patients have better outcomes than non-rheumatoid arthritis patients when hospitalized for ischemic stroke: analysis of the national inpatient sample. J Clin Rheumatol. 2022; 28:e13–7.

25. Sakr Y, Jaschinski U, Wittebole X, Szakmany T, Lipman J, Ñamendys-Silva SA, et al. Sepsis in intensive care unit patients: worldwide data from the intensive care over nations audit. Open Forum Infect Dis. 2018; 5:ofy313.

26. Kumar G, Kumar N, Taneja A, Kaleekal T, Tarima S, McGinley E, et al. Nationwide trends of severe sepsis in the 21st century (2000-2007). Chest. 2011; 140:1223–31.

27. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001; 29:1303–10.

28. Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005; 43:1130–9.

29. Quan H, Li B, Couris CM, Fushimi K, Graham P, Hider P, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011; 173:676–82.

30. Butler DC, Petterson S, Phillips RL, Bazemore AW. Measures of social deprivation that predict health care access and need within a rational area of primary care service delivery. Health Serv Res. 2013; 48(2 Pt 1):539–59.

31. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med. 2003; 348:1546–54.

32. Mohammed A, Alshamarri T, Adeyeye T, Lazariu V, McNutt LA, Carpenter DO. A comparison of risk factors for osteo- and rheumatoid arthritis using NHANES data. Prev Med Rep. 2020; 20:101242.

33. Xu Y, Wu Q. Prevalence trend and disparities in rheumatoid arthritis among US adults, 2005-2018. J Clin Med. 2021; 10:3289.

34. Funk MJ, Westreich D, Wiesen C, Stürmer T, Brookhart MA, Davidian M. Doubly robust estimation of causal effects. Am J Epidemiol. 2011; 173:761–7.

35. Li L, Greene T. A weighting analogue to pair matching in propensity score analysis. Int J Biostat. 2013; 9:215–34.

36. Austin PC. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat. 2011; 10:150–61.

37. Austin PC. Using the Standardized difference to compare the prevalence of a binary variable between two groups in observational research. Commun Stat Simul Comput. 2009; 38:1228–34.

38. Anesi GL, Liu VX, Chowdhury M, Small DS, Wang W, Delgado MK, et al. Association of ICU admission and outcomes in sepsis and acute respiratory failure. Am J Respir Crit Care Med. 2022; 205:520–8.

39. Hotchkiss RS, Monneret G, Payen D. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat Rev Immunol. 2013; 13:862–74.

40. Schulte W, Bernhagen J, Bucala R. Cytokines in sepsis: potent immunoregulators and potential therapeutic targets: an updated view. Mediators Inflamm. 2013; 2013:165974.

41. Davidson A, Diamond B. Autoimmune diseases. N Engl J Med. 2001; 345:340–50.

42. Santamaria P. Cytokines and chemokines in autoimmune disease: an overview. Adv Exp Med Biol. 2003; 520:1–7.

43. Kim W, Min S, Cho M, Youn J, Min J, Lee S, et al. The role of IL-12 in inflammatory activity of patients with rheumatoid arthritis (RA). Clin Exp Immunol. 2000; 119:175–81.

44. Nalbant S, Birlik AM. Cytokines in rheumatoid arthritis (RA). In : Sakkas LI, editor. New developments in rheumatoid arthritis. London: IntechOpen;2017. p. 55–63.

45. Reddy RC, Chen GH, Newstead MW, Moore T, Zeng X, Tateda K, et al. Alveolar macrophage deactivation in murine septic peritonitis: role of interleukin 10. Infect Immun. 2001; 69:1394–401.

46. Reddy RC, Chen GH, Tekchandani PK, Standiford TJ. Sepsis-induced immunosuppression: from bad to worse. Immunol Res. 2001; 24:273–87.

47. Ono S, Ueno C, Aosasa S, Tsujimoto H, Seki S, Mochizuki H. Severe sepsis induces deficient interferon-gamma and interleukin-12 production, but interleukin-12 therapy improves survival in peritonitis. Am J Surg. 2001; 182:491–7.

48. Baghela A, Pena OM, Lee AH, Baquir B, Falsafi R, An A, et al. Predicting sepsis severity at first clinical presentation: the role of endotypes and mechanistic signatures. EBioMedicine. 2022; 75:103776.